Status:
UNKNOWN
The NeoBeat Efficacy Study for Newborns
Lead Sponsor:
Helse Stavanger HF
Collaborating Sponsors:
Sykehuset Østfold
Laerdal Medical
Conditions:
Newborn Resuscitation
Heart Rate Monitoring
Eligibility:
All Genders
Up to 60 years
Phase:
NA
Brief Summary
In a multicenter randomized controlled trial the investigators will evaluate the efficacy of the novel heart rate meter NeoBeat on ventilation performance and short-term outcomes compared to standard ...
Detailed Description
Heart rate assessment immediately after birth in newborn infants is the most important clinical indicator to evaluate the status of a newborn, and critical to the correct guidance of resuscitation eff...
Eligibility Criteria
Inclusion
- Inborn, Gestational age ≥ 28 weeks, Multiples according to availability of equipment
Exclusion
- Congenital malformations that interfere with the intervention, Non-consent
Key Trial Info
Start Date :
March 8 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2022
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT03849781
Start Date
March 8 2019
End Date
July 1 2022
Last Update
May 15 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Stavanger University Hospital
Stavanger, Rogaland, Norway, 4068